泛型格莱卡普雷维尔/皮布伦塔斯维尔治疗儿童慢性肝炎C的治疗方法
Małgorzata Pawłowska1, Dorota Zarębska-Michaluk2, Krystyna Dobrowolska2
1From the Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Toruń.
The Pediatric infectious disease journal
|November 20, 2025
概括
一个为期8周的glecaprevir/pibrentasvir (GLE/PIB) 疗法有效地治愈了儿童的C型肝炎病毒 (HCV) 感染. 这种短期治疗耐受性良好,对于在儿童群体中实现全球HCV微清除至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 儿童传染病 儿童传染病
- 病毒学 病毒学
背景情况:
- 消除C型肝炎病毒 (HCV) 需要小儿微型消除策略.
- 像glecaprevir/pibrentasvir (GLE/PIB) 这样的泛型选择为儿童提供短期治疗.
研究的目的:
- 在患有慢性HCV感染的儿童中分析8周GLE/PIB治疗方案的疗效和耐受性.
- 评估不同儿科年龄组的GLE/PIB治疗结果.
主要方法:
- 在2022-2024年期间,对42名接受8周GLE/PIB治疗的儿童进行了回顾性分析.
- 包括在不同年龄段 (3-18岁) 接受过治疗的未经治疗的儿童,通过非侵入性弹性图谱评估肝病进展.
主要成果:
- 在每项方案的人群中,实现了100%的治愈率 (39/39).
- 8周的GLE/PIB疗法耐受性良好,罕见和轻度不良事件,主要发生在老年儿童中.
- 在老年人群中,有25%的人患有肥胖;其他并发病不常见.
结论:
- 八周的GLE/PIB疗法在所有年龄和性别的儿童中对HCV治疗非常有效和耐受.
- 实施这种疗法有助于实现消除HCV的全球目标.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247


